Archives
- 2018-07
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
Apart from its high affinity the selection
2020-06-30
Apart from its high affinity, the selection of GW2580 as TASIN-1 mg lead in our radiotracer development program was motivated by its exceptional selectivity. The observed profound impact of small structural modifications on the selected panel of four kinases tested prompted us to conduct comprehensi
-
DGK is classified into the type II
2020-06-29
DGKη is classified into the type II DGK subfamily [12], [13], [14], [15]. As described above, DGKη has the splice variants η1 and η2 [10]. DGKs η1 and η2 possess in common a pleckstrin homology domain at the N-terminus and a catalytic domain that is divided into two subdomains (catalytic subdomain-a
-
Molecular modelling studies were performed on
2020-06-29
Molecular modelling studies were performed on the hDHFR inhibitors identified (1, 11, 13, 14, 16, 25 and 32) to explore the structural basis of the interaction between the mentioned compounds and the human enzyme. The docking studies were performed using the X-ray crystallographic structure of the h
-
br Additional CDKs with a role
2020-06-29
Additional CDKs with a role in cancer Small molecule CDK inhibitors The majority of protein kinase inhibitors developed to date are type I inhibitors: they bind at the ATP–binding site, are ATP-competitive and target the kinase in its active state; with the activation loop DFG motif in the ‘in
-
The pharmacokinetics properties of compound
2020-06-29
The pharmacokinetics properties of compound were evaluated in male Sprague Dawley rats following IV (0.7mg/kg) and oral (2.0mg/kg) dosing. The total body clearance and the terminal half-life were 0.73 L/h/kg and 5.1h, respectively. After oral administration the compound showed good bioavailability (
-
This paper proposes an acceptance process
2020-06-29
This paper proposes an acceptance process and evaluation criteria, specialized for the dedication of indirect COTS SW as well as direct ones. (Step 1) It first recognizes an indirect COTS SW as a target of dedication, unlike EPRI NP-5652/TR-106439. (Step 2) It then determines the safety category of
-
Cell swelling stimulates the release
2020-06-29
Cell swelling stimulates the release of certain amino acids, in particular the non-protein amino Zoniporide dihydrochloride receptor taurine, via a pathway which has the characteristics of a channel rather than a carrier [54], [69]. Indeed, on the basis of pharmacological inhibition, it was suggeste
-
br Materials and methods BAECs CAB Toyobo
2020-06-29
Materials and methods BAECs (CAB30405, Toyobo Life Science, Osaka, Japan) were cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% Fetal Bovine Serum (04-001-1A-US, Biological Industries, Kibbutz Beit Haemek, Israel) and 1% antibiotic-antifungal agent containing 10,000-μg/mL penici
-
1568 sale br A major physiological action of ET is
2020-06-29
A major physiological action of ET-1 is to function as one of the most powerful vasoconstrictors of human blood vessels. As such, ET-1 plays a major role in regulating vascular function in all organ systems, including the kidney (Fig. 1). As in other vessels, ET-1 is thought to be released from en
-
The interface between the E ligase and the E
2020-06-29
The interface between the E3 ligase and the E2 enzyme can vary, and ZNF451 and SP-RING ligases stabilize this interaction via noncovalent binding to a scaffold SUMO (SUMOB) on the backside of the E2 (Cappadocia et al., 2015; Eisenhardt et al., 2015; Streich & Lima, 2016). By contrast, RanBP2 does no
-
Enzymatic assay The usual in vitro test
2020-06-29
Enzymatic assay. The usual in vitro test for the measure of the activity of DbH involves ascorbate as a cosubstrate (e.g., 5mM) and tyramine as a substrate (e.g., 10mM). When using N-aryl-N′-hydroxyguanidines instead of ascorbate, the hydroxylase activity of DbH was measured by HPLC as the amounts o
-
While these previous correlative studies have measured tDDR
2020-06-28
While these previous correlative studies have measured tDDR1 protein by IHC, these studies have not considered that pDDR1 could also be an important marker of cancer prognosis. A phosphoproteomic survey of lung cancer tissues did identify pDDR1 as one of the most commonly phosphorylated receptor kin
-
It is worth mentioning that in
2020-06-28
It is worth mentioning that, in this study we only observed the responses of CYP450 to the short-term exposure of DSP toxins (12 h). However, the toxic effects of DSP toxins to bivalves appeared to abate with longer exposure (Pinto-Silva et al., 2005; Flórez-Barrós et al., 2011; Prego-Faraldo et al.
-
The different diagnostic outcomes of the
2020-06-28
The different diagnostic outcomes of the two assays are also dependent on the used stimuli. The QuantiFERON-CMV assay targets CD8 + T PPM-18 synthesis by using peptides whereas the T-Track-CMV targets CD4+ and CD8 + T cells by stimulation with two viral proteins [18]. In our study, a specificity o
-
br Roles for intracellular chloride channels br Specific
2020-06-28
Roles for intracellular chloride channels Specific chloride channel proteins in intracellular membranes Concluding remarks Introduction The sulfonylurea derivative glybenclamide (GLYB) is used as oral hypoglycemic agent to treat non-insulin dependent diabetes mellitus [1], [2]. The antid
15218 records 841/1015 page Previous Next First page 上5页 841842843844845 下5页 Last page